Basic Information
| LncRNA/CircRNA Name | LINC00152 |
| Synonyms | CYTOR, C2orf59, LINC00152, NCRNA00152 |
| Region | GRCh38_2:87454781-87636740 |
| Ensemble | ENSG00000222041 |
| Refseq | NR_024204 |
Classification Information
| Regulatory Mechanism | Biological Function | Clinical Application | |||
|---|---|---|---|---|---|
| TF | Immune | Survival | |||
| Enhancer | Apoptosis | apoptosis | Drug | ||
| Variant | Cell Growth | Circulating | |||
| MiRNA | EMT | Metastasis | |||
| Methylation | Coding Ability | Recurrence |
Cancer&Entry Information
| Cancer Name | osteosarcoma |
| ICD-0-3 | NA |
| Methods | qRT-PCR , Luciferase reporter assay , in vitro knockdown etc. |
| Sample | human osteosarcoma cell lines(U2OS, Saos-2, MG63 and MNNG/HOS), as well as the human osteoblast cell line HFOB 1.19, |
| Expression Pattern | up-regulated |
| Function Description | LINC00152 is overexpressed in osteosarcoma cells, leading to increased cell proliferation, and decreased G0/G1 cell cycle arrest and apoptosis. The binding of miR-193b-3p to LINC00152 was demonstrated by dual-luciferase assay, and led to miR-193b-3p downregulation in osteosarcoma cells. Knockdown of LINC00152 revealed an antitumorigenic effect by reducing cell proliferation and increasing G0/G1 arrest and apoptosis. Inhibiting miR-193b-3p reversed the effects of LINC00152 knockdown. |
| Pubmed ID | 31579407 |
| Year | 2019 |
| Title | Long Non-Coding RNA LINC00152 Promotes Tumorigenesis via Sponging miR-193b-3p in Osteosarcoma |
External Links
| Links for LINC00152 | GenBank HGNC NONCODE |
| Links for osteosarcoma | OMIM COSMIC |